Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

Supratentorial Primitive Neuroectodermal Tumors in Children Homepage

This page was last updated on June 9th, 2022



Ash Singhal, M.D.

Paul Steinbok, M.D.

Section Editor

Kristian Aquilina, M.D.

Editor in Chief

Rick Abbott, M.D.


Supratentorial PNETs are rare, highly malignant, embryonal tumors, which are similar in histology to pineoblastomas and medulloblastomas. They tend to present early in childhood and the symptoms are rapid in evolution. The expected survival rate after multimodality treatment that includes surgical resection followed by radiation and chemotherapy is 40-45%.

Key Points

  • Different from posterior fossa PNET: While supratentorial PNETs are similar to posterior fossa PNETs (aka medulloblastomas) morphologically, these tumors are different cytogenically.
  • Metastasis predicts treatment failure: Metastasis at the time of initial diagnosis predicts failure of local treatments.
  • Reoperation for local recurrence: If there is recurrence of tumor locally then surgical resection is seriously considered.  Recurrence at a distal site is handled with radiation or chemotherapy.

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.